{
  "created_at": "Mon Nov 29 7:49:5 +0000 2021",
  "id_str": "1465155574056824833",
  "full_text": "Most promising of all are new antiviral drugs: Pfizer is already manufacturing “significant quantities” of its protease inhibitor, while the US government has agreed to buy 1.2bn courses of a treatment from Merck https://t.co/QiCx43Do6O",
  "display_text_range": [
    0,
    236
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/QiCx43Do6O",
        "expanded_url": "https://econ.st/3DGtLxF",
        "display_url": "econ.st/3DGtLxF",
        "indices": [
          213,
          236
        ]
      }
    ]
  },
  "user": {
    "name": "The Economist",
    "screen_name": "TheEconomist",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/879361767914262528/HdRauDM-_normal.jpg"
  },
  "retweet_count": 31,
  "favorite_count": 90,
  "possibly_sensitive": false,
  "original_created_at": "Mon Nov 29 03:08:04 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "中でも最も期待されているのは、新しい抗ウイルス剤です。ファイザー社はすでにプロテアーゼ阻害剤を「かなりの量」製造しており、米国政府はメルク社から12億コースの治療薬を購入することに合意しています https://t.co/QiCx43Do6O"
    },
    {
      "locale": "zh",
      "full_text": "其中最有希望的是新的抗病毒药物。辉瑞公司已经在生产 \"大量 \"的蛋白酶抑制剂，而美国政府已经同意从默克公司购买12亿个疗程的治疗药物https://t.co/QiCx43Do6O。"
    },
    {
      "locale": "zh-Hant",
      "full_text": "其中最有希望的是新的抗病毒藥物。輝瑞公司已經在生產 \"大量 \"的蛋白酶抑制劑，而美國政府已經同意從默克公司購買12億個療程的治療藥物https://t.co/QiCx43Do6O。"
    }
  ]
}